in vivo cell therapy

News

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics, a developer of in vivo cell therapies, for $1.5bn in cash.

News

A pioneer of in vivo cell therapy, Umoja has cleared another regulatory milestone by getting fast-track status for its lead blood cancer programme.

News

Gilead's Kite unit has reached an agreement to buy Interius BioTherapeutics, boosting its in vivo cell therapy credentials.

News

AbbVie has agreed to buy Capstan for up to $2.1bn, expanding its pipeline with an in vivo CAR-T therapy for autoimmune diseases.

R&D

Oncology

In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.